Status:

COMPLETED

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Chemotherapy-induced Nausea and Vomiting (CINV)

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.

Eligibility Criteria

Inclusion

  • Cycle 1:
  • Patient is scheduled to receive his/her first course of cisplatin chemotherapy at a dose of at least 70 mg/m\^2 administered a maximum of 3 hours
  • Patient has a predicted life expectancy of at least 3 months
  • Patient is not pregnant
  • Cycle 2 (optional):
  • Participation in the study during the next cycle of chemotherapy is considered
  • appropriate by the investigator and will not pose unwarranted risk to the patient.
  • Satisfactory completion of the preceding cycle of chemotherapy and related
  • study procedures.
  • Patient will continue to receive the same chemotherapy regimen as in Cycle 1. The cisplatin dose may be reduced in subsequent cycle, as long as the new
  • dose is still no less than 70 mg/m\^2.

Exclusion

  • Cycles 1 \& 2:
  • Patient will receive stem cell therapy in conjunction with cisplatin
  • Patient has an active infection or any uncontrolled disease (e.g. diabetes)
  • Patient will receive multiple-day chemotherapy with cisplatin
  • Patient will receive chemotherapy of moderate or high emetogenicity on the 6 days prior to cisplatin infusion or the 6 days following the cisplatin infusion
  • Patient has vomited within 24 hours prior to cisplatin infusion
  • Patient received or will receive radiation therapy to the abdomen

Key Trial Info

Start Date :

August 25 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 5 2010

Estimated Enrollment :

421 Patients enrolled

Trial Details

Trial ID

NCT00952341

Start Date

August 25 2009

End Date

May 5 2010

Last Update

June 2 2017

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED) | DecenTrialz